Halozyme Therapeutics announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026.

Exelixis, Inc. filed an 8-K on March 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The press release, furnished as Exhibit 99.

Ionis Pharmaceuticals announced significant changes to its Board of Directors. B. Lynne Parshall and Joseph H. Wender will retire at the end of their terms in June 2026.

Perrigo Company plc released its fourth-quarter earnings for the period ending December 31, 2025, via an 8-K filing with the SEC.

BeOne Medicines Ltd. (BGNE) filed an 8-K announcing its financial results for the fourth quarter and full year 2025. The press release, included as Exhibit 99.

Ionis Pharmaceuticals filed an 8-K on February 25, 2026, reporting its financial results for the quarter and fiscal year ended December 31, 2025.

Elanco Animal Health (ELAN) filed an 8-K on February 24, 2026, reporting its financial results for the full year and fiscal quarter ended December 31, 2025.

BioMarin Pharmaceutical Inc. filed an 8-K on February 23, 2026, announcing its financial results for the fourth quarter ended December 31, 2025. The filing includes a press release (Exhibit 99.

Gilead Sciences has announced a definitive agreement to acquire Arcellx, Inc. through a tender offer. Gilead's subsidiary, Ravens Sub, Inc., will offer $115.

Halozyme Therapeutics, Inc. filed an 8-K on February 17, 2026, reporting its financial results for the fourth quarter ended December 31, 2025. The filing includes a press release (Exhibit 99.